Homozygous deletion of the HLA-B gene as an acquired-resistance mechanism to nivolumab in a patient with lung adenocarcinoma: a case report

Immune checkpoint inhibitors (ICIs) have greatly improved the treatment of advanced non-small-cell lung cancer, including lung adenocarcinoma (LUAD). Patients treated with ICIs can have long-term clinical outcomes; however, acquired resistance to ICI therapy has been frequently observed. To date, li...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, He, Dong, Weiwei, Zhao, Huixia, Zeng, Zhiyan, Zhang, Fengyun, Hu, Yanyan, Li, Qiuwen, Chen, Jing, Meng, Erhong, Xiao, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573430/
https://www.ncbi.nlm.nih.gov/pubmed/34805368
http://dx.doi.org/10.21037/atm-21-3825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573430/
https://www.ncbi.nlm.nih.gov/pubmed/34805368
http://dx.doi.org/10.21037/atm-21-3825

Ejemplares similares